Himalaya targets 12 percent growth in FY15

The company is eyeing 12 percent revenue growth, about Rs 1450 crore in the current Financial Year (FY15)

id-100175153

In the FY14, the company generated Rs 1,300 crore

In the current fiscal year, Himalaya Drug Company is targeting 12 percent revenue growth, about Rs 1450 crore on robust sales in the domestic market. In the FY14, the company generated Rs 1,300 crore.

"We are looking at clocking Rs 1,450 crore in revenue in the current fiscal year. Our revenue growth is primarily driven by growth in the domestic market," said the company's CEO Mr Philipe Haydon in a statement. He added, "We are constantly exploring new routes to penetrate our brand across new categories, existing markets, new markets, and multiple demographics."

Speaking about the company's business plans, he further added, "Our research pipeline is robust. We are in the advanced stage of drug development for cancer. We are also strengthening our presence in the nutraceuticals segment."

Pharmaceutical and personal care contribute majority of the company's revenue, about 38 percent each. The remaining is contributed by baby care and animal health business.

 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X